Compare Stocks → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AHACNASDAQ:CLLSNASDAQ:MACUNASDAQ:MOLN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAHACAlpha Healthcare Acquisition$10.96$10.41$9.12▼$16.96$140.89MN/A341,126 shs298,128 shsCLLSCellectis$3.06-5.6%$2.66$0.96▼$3.77$170.09M3.0884,803 shs131,617 shsMACUMallard Acquisition$10.09$9.97$9.66▼$10.48$138.74M-0.0676,784 shs1 shsMOLNMolecular Partners$3.80+2.7%$3.93$3.32▼$7.32$138.20M0.794,186 shs661 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAHACAlpha Healthcare Acquisition0.00%0.00%0.00%0.00%0.00%CLLSCellectis0.00%+2.34%+9.29%0.00%+59.38%MACUMallard Acquisition0.00%0.00%0.00%0.00%0.00%MOLNMolecular Partners0.00%-4.52%-1.55%-17.39%-42.77%Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAHACAlpha Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACLLSCellectis2.6287 of 5 stars3.52.00.00.03.32.50.6MACUMallard AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMOLNMolecular Partners0.9194 of 5 stars2.03.00.00.02.70.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAHACAlpha Healthcare AcquisitionN/AN/AN/AN/ACLLSCellectis3.00Buy$8.50177.78% UpsideMACUMallard AcquisitionN/AN/AN/AN/AMOLNMolecular Partners2.00Hold$4.5018.42% UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAHACAlpha Healthcare AcquisitionN/AN/A$0.12 per share92.25$0.39 per shareN/ACLLSCellectis$9.19M18.51N/AN/A$1.52 per share2.01MACUMallard AcquisitionN/AN/AN/AN/A($1.32) per shareN/AMOLNMolecular Partners$7.84M17.63N/AN/A$5.41 per share0.70Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAHACAlpha Healthcare Acquisition$1.42MN/A0.00∞N/AN/AN/AN/AN/ACLLSCellectis-$101.06M-$1.72N/AN/AN/A-1,087.66%-99.88%-36.89%5/16/2024 (Estimated)MACUMallard Acquisition-$3.06MN/A0.00∞N/AN/AN/AN/AN/AMOLNMolecular Partners-$69.04M-$2.12N/AN/AN/A-885.11%-31.10%-27.93%N/ALatest AHAC, MOLN, MACU, and CLLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2024Q4 2023CLLSCellectisN/A-$0.64-$0.64-$0.64N/A$1.99 million3/14/2024Q4 2023MOLNMolecular PartnersN/A-$0.68-$0.68-$0.68N/A$1.17 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAHACAlpha Healthcare AcquisitionN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AMACUMallard AcquisitionN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAHACAlpha Healthcare AcquisitionN/A2.102.10CLLSCellectis0.581.501.50MACUMallard AcquisitionN/A0.670.67MOLNMolecular PartnersN/A13.3513.35OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAHACAlpha Healthcare Acquisition19.00%CLLSCellectis63.90%MACUMallard Acquisition79.30%MOLNMolecular Partners26.55%Insider OwnershipCompanyInsider OwnershipAHACAlpha Healthcare AcquisitionN/ACLLSCellectis16.41%MACUMallard Acquisition20.00%MOLNMolecular Partners5.93%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAHACAlpha Healthcare AcquisitionN/A12.86 millionN/ANot OptionableCLLSCellectis23155.58 million46.46 millionOptionableMACUMallard Acquisition213.75 million11.00 millionNot OptionableMOLNMolecular Partners16736.37 million34.21 millionNot OptionableAHAC, MOLN, MACU, and CLLS HeadlinesSourceHeadlineMOLN Molecular Partners AGseekingalpha.com - May 1 at 6:21 PMMolecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Actionfinance.yahoo.com - April 29 at 2:14 PMMolecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Actionglobenewswire.com - April 29 at 11:00 AMLife Science Cares Launches in Switzerlandglobenewswire.com - April 19 at 11:12 AMWe Think Molecular Partners (VTX:MOLN) Needs To Drive Business Growth Carefullyfinance.yahoo.com - April 18 at 2:20 AMMolecular Partners Announces All Board Proposals Approved at the Annual General Meetingglobenewswire.com - April 17 at 11:12 AMBeyond Benign, MilliporeSigma partner on green chemistrybizjournals.com - April 4 at 7:47 PMMolecular Partners Publishes Invitation to Annual General Meeting 2024globenewswire.com - March 26 at 9:26 AMLeerink Partners Keeps Their Hold Rating on Molecular Partners (MOLN)markets.businessinsider.com - March 21 at 9:32 AMMolecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023globenewswire.com - March 14 at 4:00 PMMolecular Partners AG (spons. ADRs) hosts conference call for investorsmarkets.businessinsider.com - March 13 at 1:23 PMThe past three years for Molecular Partners (VTX:MOLN) investors has not been profitablefinance.yahoo.com - March 13 at 8:22 AMMolecular Partners wins dismissal of securities lawsuituk.investing.com - March 2 at 10:41 PMMolecular Partners Announces Dismissal of Class Action Lawsuitglobenewswire.com - March 1 at 4:17 PMMolecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentationsglobenewswire.com - March 1 at 4:00 PMNew £1.5m Centre could unlock the secrets of diseases, molecule-by-moleculealphagalileo.org - February 5 at 8:31 AMStrategic Alliances In The Low Molecular Hyaluronic Acid Marketopprairie.com - February 4 at 12:58 AMMolecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 7 at 4:40 PMMolecular Partners, Orano to collaborate on RDT therapies for cancermsn.com - January 5 at 5:30 PMMolecular Partners AG (6ML0.MU)ca.finance.yahoo.com - December 31 at 7:59 PMMolecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meetingfinance.yahoo.com - December 10 at 2:06 PMMolecular Partners AG ADR MOLNmorningstar.com - November 11 at 8:05 AMMolecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Expositionfinance.yahoo.com - November 2 at 7:43 AMMolecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summitfinance.yahoo.com - November 1 at 5:39 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAlpha Healthcare AcquisitionNASDAQ:AHACAlpha Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.CellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Mallard AcquisitionNASDAQ:MACUMallard Acquisition Corp. does not have significant operations. It focuses on the effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Cornelius, North Carolina.Molecular PartnersNASDAQ:MOLNMolecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.